Immunitet opnås generelt inden for 3 uger som vist i den pivotale, kliniske fase III- undersøgelse V58P4 for den voksne og ældre population.
Seroprotection is generally obtained within 3 weeks, as shown by the pivotal phase III clinical study V58P4 for the adult and elderly population.